Clinical Trial

The Holistic Study

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-02.
Trial Details
NCT Number NCT07051915
Lead Sponsor Ostfold Hospital Trust
Collaborators: Oslo University Hospital, University Hospital, Akershus, Sykehuset i Vestfold HF, St. Olavs Hospital, Helse Stavanger HF, Sorlandet Hospital HF, University Hospital of North Norway, Haukeland University Hospital, Helse Nord-Trøndelag HF, Helse Fonna, Nordlandssykehuset HF
Conditions Thrombocytopenia Purpura
Enrollment 220 participants
Start Date 2025-09-15
Primary Completion 2028-01-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-09